For example, the resistance to endocrine therapies is primarily facilitated by the molecular modification from estrogen-dependent to estrogen-independent status in ER+ (estrogen-receptor positive) breast cancer cells; however, the mechanism via which the MAPK/ERK pathway is involved in estrogen-independent breast cancer is not understood. The gene discussed is ESR1; the disease is breast carcinoma.